Gian Life Care Ltd.
Snapshot View

28.95 -1.50 ▼-4.9%

02 August 2021, 04:00:00 P.M.
Volume: 18,000

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Hospital & Healthcare Services Compare with Industry peers
Website http://www.gianpathlabs.com
Financial Indicators
Market Cap 14.31 Cr.
Earnings per share (EPS) 4.29 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 7.10 Trailing Twelve Months Ending 2021-03
Industry PE 227.26 Trailing Twelve Months Ending 2021-03
Book Value / Share 20.66 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.47 Calculated using Price: 30.45
Dividend Yield 0.00 Period Ending 2019-03
No. of Shares Subscribed 0.47 Cr. 4,700,694 Shares
FaceValue 10
Company Profile

Gian Life Care was incorporated on November 06, 2018, under the provisions of the Companies Act, 2013 by Registrar of Companies, Kanpur. On March 01, 2019 the company took over the entire running business of Gian Pathology and X-Rays, a proprietorship concern of the promoter Arun Kumar Gupta with a view to provide diagnostic and related healthcare tests and services.

Business area of the Company:

The company is engaged in the business of providing diagnostic and related healthcare services. The company provides a wide range of diagnostic tests and services like patient diagnosis services, prevention, and wellness diagnosis services to patients and healthcare providers. The company caters to individual patients, hospitals, corporates and other healthcare providers. The company offers various tests including biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, histopathology, immunoassay, microbiology, molecular biology, and radiology services.

Key Events and Milestones:

  • 2018: Incorporation of the company in the name of ‘Gian Life Care Limited’
  • 2019: Acquired the running business along with substantial assets and liabilities of Gian Pathology and X rays, proprietorship concern of the Promoter.

 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.93%
1 Week
-14.35%
1 Month
-9.53%
3 Month
+93.00%
6 Month
+18.65%
1 Year
+6.83%
2 Year
5 Year
1 years 2019-03
Return on Equity (%) 235.68
Return on Capital Employed (%) 12.85
Return on Assets (%) 1.28

Balance Sheet View Details

Particulars 1 years 2019-03 Rs. Cr.
Shh. Funds 0
Non Curr. Liab. 1
Curr. Liab. 7
Minority Int.
Equity & Liab. 8
Non Curr. Assets 4
Curr. Assets 3
Misc. Exp. not W/O 0
Total Assets 8

Profit Loss View Details

Particulars 1 years 2019-03 Rs. Cr.
Net Sales 1
Other Income
Total Income 1
Total Expenditure 0
PBIDT 0
Interest 0
Depreciation 0
Taxation 0
Exceptional Items
PAT 0

Cash Flow View Details

Particulars 1 years 2019-03 Rs. Cr.
Cash Fr. Operatn. 3
Cash Fr. Inv. -3
Cash Fr. Finan. 1
Net Change 1
Cash & Cash Eqvt 1

Shareholding Pattern View Details

3 Qtrs 2020-03 (%) 2020-09 (%) 2021-03 (%)
Promoter 69.87 69.87 69.87
Public 30.13 30.13 30.13
Depository Receipts 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00

Announcements View Details

Wed, 21 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- Arun Kumar Gupta
Designation :- Managing Director / Whole Time Director
Wed, 07 Jul 2021
Outcome Of Board Meeting Held On Wednesday 07Th July 2021
Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors at their meeting held today i.e. 07th July 2021 has inter-alia considered and approved the following:

a. Approved Standalone Financial Statements for the half year and year ended 31st March 2021.


The Board Meeting commenced at 05:00 P.M and concluded at 05:45 P.M.
Wed, 07 Jul 2021
Audited Financial Results For The Half Year And Year Ended 31St March 2021
Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors at their meeting held today i.e. 07th July 2021 has inter-alia considered and approved the following:

a. Approved Standalone Financial Statements for the half year and year ended 31st March 2021.

Technical Scans View Details

Tue, 27 Jul 2021
High Delivery Percentage High Delivery Percentage
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Opening at High Opening at High
Opening at Low Opening at Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.45 +0.1%
Divi's Laboratories Ltd. 129,702.64 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,701.80 -0.2%
Cipla Ltd. 74,235.31 921.80 +0.2%
Cadila Healthcare Ltd. 59,986.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,049.00 +0.4%
Aurobindo Pharma Ltd. 53,701.27 918.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.87 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 918.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.05 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 918.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 918.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 918.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 918.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 918.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 918.00 +0.1%